Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
| Status: | Archived |
|---|---|
| Conditions: | Ovarian Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | October 2010 |
| End Date: | October 2020 |
Phase I Study of Intraperitoneal Carboplatin With Intravenous Paclitaxel and Bevacizumab in Patients With Previously Untreated Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma
Phase I study to evaluate intraperitoneal carboplatin along with weekly intravenous
paclitaxel and bevacizumab in order to establish a tolerable dose and define the toxicity of
this regimen in previously untreated patients with advanced ovarian carcinoma.
Phase I study with the primary objective to determine the maximum tolerated dose of
intraperitoneal carboplatin and intravenous weekly paclitaxel given in combination with
intravenous bevacizumab during the second two cycles of treatment in patients with
chemo-naive epithelial ovarian, primary peritoneal or fallopian tube cancer. The maximum
tolerated dose is defined as the highest dose at which no more than 1 of 6 evaluable
patients experiences a dose limiting toxicity during the second two cycles of treatment.
Secondary objectives are to determine response rates and to estimate progression free
survival and overall survival of this class of patients.
We found this trial at
1
site
Click here to add this to my saved trials
